Sodium bicarbonate
Identification
- Name
- Sodium bicarbonate
- Accession Number
- DB01390
- Description
Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Sodium bicarbonate (DB01390)
- Weight
- Average: 84.0066
Monoisotopic: 83.982338573 - Chemical Formula
- CHNaO3
- Synonyms
- Baking soda
- Bicarbonate of soda
- Carbonic acid monosodium salt
- NaHCO3
- Natriumhydrogenkarbonat
- Sodio bicarbonato
- Sodium acid carbonate
- Sodium hydrogen carbonate
- Sodium hydrogencarbonate
- External IDs
- B1654
- E 500
- E-500
- E-500(II)
- E500
- INS NO.500(II)
- INS-500(II)
Pharmacology
- Indication
Sodium bicarbonate is used for the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturateprotein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments.
- Associated Conditions
- Acid indigestion
- Barbiturate intoxication
- Breast Cancer
- Constipation
- Dental Decay
- Duodenal Ulcer
- Dyspepsia
- Gastro-esophageal Reflux Disease (GERD)
- Gingival Bleeding
- Heartburn
- Helicobacter Infections
- Hyperkalemia
- Ischaemia
- Metabolic Acidosis
- Myocardial Infarction
- Plaque, Dental
- Pruritis of the skin
- Skin Irritation
- Upset stomach
- Zollinger-Ellison Syndrome
- Abdominal bloating
- Benign, active Gastric Ulcer
- Methyl alcohol poisoning
- Prophylaxis of Contrast-induced nephropathy
- Salicylate poisoning
- Severe Diarrhea
- Swelling of the gums
- Associated Therapies
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
Intravenous sodium bicarbonate therapy increases plasma bicarbonate, buffers excess hydrogen ion concentration, raises blood pH and reverses the clinical manifestations of acidosis.
- Mechanism of action
Sodium bicarbonate is a systemic alkalizer, which increases plasma bicarbonate, buffers excess hydrogen ion concentration, and raises blood pH, thereby reversing the clinical manifestations of acidosis. It is also a urinary alkalizer, increasing the excretion of free bicarbonate ions in the urine, thus effectively raising the urinary pH. By maintaining an alkaline urine, the actual dissolution of uric acid stones may be accomplished. Sodium bicarbonate acts as an antacid and reacts chemically to neutralize or buffer existing quantities of stomach acid but has no direct effect on its output. This action results in increased pH value of stomach contents, thus providing relief of hyperacidity symptoms. [PharmGKB]
Target Actions Organism AHydrogen ions neutralizer- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAcetaminophen Sodium bicarbonate can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy. Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Sodium bicarbonate. Acetophenazine Sodium bicarbonate can cause a decrease in the absorption of Acetophenazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Alendronic acid The serum concentration of Alendronic acid can be decreased when it is combined with Sodium bicarbonate. Alimemazine Sodium bicarbonate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Allopurinol The therapeutic efficacy of Allopurinol can be decreased when used in combination with Sodium bicarbonate. Amphetamine The serum concentration of Amphetamine can be increased when it is combined with Sodium bicarbonate. Amprenavir Sodium bicarbonate can cause a decrease in the absorption of Amprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy. Asunaprevir Sodium bicarbonate can cause a decrease in the absorption of Asunaprevir resulting in a reduced serum concentration and potentially a decrease in efficacy. Atazanavir Sodium bicarbonate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy. Additional Data Available- Extended DescriptionExtended DescriptionAvailable for Purchase
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - SeveritySeverityAvailable for Purchase
A severity rating for each drug interaction, from minor to major.
Learn more - Evidence LevelEvidence LevelAvailable for Purchase
A rating for the strength of the evidence supporting each drug interaction.
Learn more - ActionActionAvailable for Purchase
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Take with or without food. Many different products contain sodium bicarbonate; refer to the product monograph for more specific instruction.
Products
- Active Moieties
Name Kind UNII CAS InChI Key Carbon dioxide unknown 142M471B3J 124-38-9 CURLTUGMZLYLDI-UHFFFAOYSA-N Sodium cation ionic LYR4M0NH37 17341-25-2 FKNQFGJONOIPTF-UHFFFAOYSA-N Bicarbonate ion ionic HN1ZRA3Q20 71-52-3 BVKZGUZCCUSVTD-UHFFFAOYSA-M - Product Images
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Unlock Additional Data7.5% Sodium Bicarbonate Injection, solution 75 mg/1mL Intravenous HF Acquisition Co LLC, DBA HealthFirst 2020-01-29 Not applicable US 
8.4% Sodium Bicarbonate Injection, solution 84 mg/1mL Intravenous HF Acquisition Co. LLC, DBA HealthFirst 2018-09-01 Not applicable US 800 Sodium Bicarbonate Powder Powder, for solution Hemodialysis Baxter Laboratories 1988-12-31 Not applicable Canada 
Bibag Powder, for solution Hemodialysis Fresenius Medical Care Deutchland Gmbh 2020-01-30 Not applicable Canada Bibag Powder, for solution Hemodialysis Fresenius Medical Care Deutchland Gmbh 2009-12-10 Not applicable Canada Bicarb Hemodial Conc 81.25gm/l Liquid Hemodialysis Bicarbolyte Corporation 1986-12-31 1998-06-08 Canada Bicarbolyte Bicar Hemodialysis Conc Liquid Hemodialysis Bicarbolyte Corporation 1986-12-31 1998-06-08 Canada Bicarbonate Conc Mb-330 Pwr 650mg/pck Powder Hemodialysis Renal Systems, Division Of Minntech Corp. 1985-12-31 1998-11-02 Canada Bicarbonate Concentrate 4105 Liquid Hemodialysis Baxter Laboratories 1988-12-31 2002-08-01 Canada Bicarbonate Concentrate B38 Solution Hemodialysis Chief Medical Supplies Ltd 2005-07-04 Not applicable Canada Additional Data Available- Application NumberApplication NumberAvailable for Purchase
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct CodeAvailable for Purchase
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Unlock Additional DataSodium Bicarbonate Injection, solution 75 mg/1mL Intravenous Hospira, Inc. 2006-05-18 2008-10-01 US Sodium Bicarbonate Injection, solution 75 mg/1mL Intravenous Hospira, Inc. 2020-07-23 Not applicable US Sodium Bicarbonate Injection, solution 42 mg/1mL Intravenous General Injectables & Vaccines, Inc. 2019-11-11 Not applicable US Sodium Bicarbonate Injection, solution 84 mg/1mL Intravenous Exela Pharma Sciences, LLC 2019-08-01 Not applicable US Sodium Bicarbonate Injection 84 mg/1mL Intravenous Remedy Repack 2018-01-12 2018-03-08 US Sodium Bicarbonate Injection 84 mg/1mL Intravenous Medical Purchasing Solutions, Llc 2000-06-01 Not applicable US Sodium Bicarbonate Injection, solution 84 mg/1mL Intravenous Civica 2019-08-01 Not applicable US Sodium Bicarbonate Injection, solution 84 mg/1mL Intravenous Hospira, Inc. 2020-07-23 Not applicable US Sodium Bicarbonate Injection 84 mg/1mL Intravenous International Medication Systems, Limited 2000-06-01 Not applicable US Sodium Bicarbonate Injection, solution 42 mg/1mL Intravenous Exela Pharma Sciences, LLC 2019-08-01 Not applicable US Additional Data Available- Application NumberApplication NumberAvailable for Purchase
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct CodeAvailable for Purchase
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Unlock Additional DataAfter Bite Advanced Liquid 50 mg/1mL Topical Adventure Ready Brands 2020-09-01 Not applicable US After Bite Advanced Liquid 50 mg/1mL Topical Adventure Ready Brands 2021-01-01 Not applicable US After Bite Kids Liquid 5 g/100g Topical Adventure Ready Brands 2020-09-01 Not applicable US After Bite Kids Liquid 5 g/100g Topical Tender Corporation 2014-11-26 2020-09-30 US After Bite Sensitive Liquid 5 g/100g Topical Tender Corporation 2014-11-26 Not applicable US After Bite the Itch Eraser Liquid 50 mg/1mL Topical Tender Corporation 2014-09-02 2020-09-30 US After Bite The Itch Eraser KIDS Liquid 5 g/100g Topical Tender Corporation 2014-11-25 2014-11-25 US After Bite The Itch Eraser KIDS Liquid 5 g/100g Topical Tender Corporation 2014-11-26 2014-11-26 US After Bite Wipe Swab 50 mg/1mL Topical Tender Corporation 2019-07-01 Not applicable US Anti-Empacho Liquid 525 mg/15mL Oral Menper Distributors, Inc. 2012-02-21 Not applicable US Additional Data Available- Application NumberApplication NumberAvailable for Purchase
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct CodeAvailable for Purchase
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Adea Gargle Sodium bicarbonate (36.2 g/100mg) + Xylitol (5 g/100mg) Tablet, chewable Oral K2resource Co., Ltd. 2018-03-01 2018-04-01 US Adea Gargle Sodium bicarbonate (36.2 g/100mg) + Xylitol (5 g/100mg) Tablet, chewable Oral K2resource Co., Ltd. 2018-03-01 Not applicable US Alka Seltzer Sodium bicarbonate (1916 mg/1) + Acetylsalicylic acid (325 mg/1) + Citric acid (1000 mg/1) Tablet, effervescent Oral Salimex, S.A. 2012-10-10 Not applicable US Alka Seltzer Sodium bicarbonate (1916 mg/1) + Acetylsalicylic acid (325 mg/1) + Citric acid (1000 mg/1) Tablet, effervescent Oral Salimex, S.A. 2012-10-10 Not applicable US Alka Seltzer Evt Sodium bicarbonate (1.916 g) + Acetylsalicylic acid (325 mg) + Citric acid (1 g) Tablet, effervescent Oral Miles Inc. Pharmaceutical Division 1977-12-31 1996-09-09 Canada Alka Seltzer Flavoured Sodium bicarbonate (1.71 g) + Acetylsalicylic acid (325 mg) + Citric acid (1.22 g) Tablet, effervescent Oral Miles Inc. Pharmaceutical Division 1986-12-31 1996-09-09 Canada Alka Seltzer Original Sodium bicarbonate (1916 mg/1) + Acetylsalicylic acid (325 mg/1) + Citric acid (1000 mg/1) Tablet, effervescent Oral Navajo Manufacturing Company Inc. 2016-09-16 Not applicable US Alka Seltzer Original Sodium bicarbonate (1916 mg/1) + Acetylsalicylic acid (325 mg/1) + Citric acid (1000 mg/1) Tablet, effervescent Oral Savings Distributors LLC 2019-07-01 Not applicable US Alka-Seltzer Sodium bicarbonate (1916 mg) + Acetylsalicylic acid (325 mg) + Citric acid (1000 mg) Tablet, effervescent Oral Bayer 1995-12-31 Not applicable Canada Alka-Seltzer Sodium bicarbonate (1916 mg/1) + Acetylsalicylic acid (325 mg/1) + Citric acid (1000 mg/1) Tablet, effervescent Oral Lil' Drug Store Products, Inc 2000-01-01 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image 7.5% Sodium Bicarbonate Sodium bicarbonate (75 mg/1mL) Injection, solution Intravenous HF Acquisition Co LLC, DBA HealthFirst 2020-01-29 Not applicable US 8.4% Sodium Bicarbonate Sodium bicarbonate (84 mg/1mL) Injection, solution Intravenous HF Acquisition Co. LLC, DBA HealthFirst 2018-09-01 Not applicable US Adea Gargle Sodium bicarbonate (36.2 g/100mg) + Xylitol (5 g/100mg) Tablet, chewable Oral K2resource Co., Ltd. 2018-03-01 2018-04-01 US Adea Gargle Sodium bicarbonate (36.2 g/100mg) + Xylitol (5 g/100mg) Tablet, chewable Oral K2resource Co., Ltd. 2018-03-01 Not applicable US Aqua De Folli Hair Booster Sodium bicarbonate (0.006 g/100mL) + Magnesium sulfate (0.00024 g/100mL) + Zinc sulfate, unspecified form (0.0000022 g/100mL) Liquid Topical ROKIT HEALTHCARE Inc. 2020-09-24 Not applicable US Aqua De Folli Hair Booster Mini Sodium bicarbonate (0.006 g/100mL) + Magnesium sulfate (0.00024 g/100mL) + Zinc sulfate, unspecified form (0.0000022 g/100mL) Liquid Topical ROKIT HEALTHCARE Inc. 2020-09-24 Not applicable US Aqua De Folli Hair Booster Pro Sodium bicarbonate (0.006 g/100mL) + Magnesium sulfate (0.00024 g/100mL) + Zinc sulfate, unspecified form (0.0000022 g/100mL) Liquid Topical ROKIT HEALTHCARE Inc. 2020-09-24 Not applicable US Assured Bug Bite Relief Sodium bicarbonate (5 g/100g) Liquid Topical Shanghai Weierya Daily Chemicals Factory 2015-11-10 Not applicable US Cvs Sodium bicarbonate (22.8 mg/100mg) + Sodium chloride (77.8 mg/100mg) Nasal CVS Pharmacy, Inc. 2017-04-24 Not applicable US Cvs Sodium bicarbonate (22.8 mg/100mg) + Sodium chloride (77.8 mg/100mg) Kit Nasal CVS PHARMACY 2016-03-25 Not applicable US
Categories
- ATC Codes
- B05CB04 — Sodium bicarbonate
- B05CB — Salt solutions
- B05C — IRRIGATING SOLUTIONS
- B05 — BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
- B — BLOOD AND BLOOD FORMING ORGANS
- Drug Categories
- Acids
- Acids, Noncarboxylic
- Alkalies
- Anions
- Antacids
- Antacids and Adsorbents
- Bicarbonates
- Blood and Blood Forming Organs
- Blood Substitutes and Perfusion Solutions
- Carbon Compounds, Inorganic
- Carbonates
- Carbonic Acid
- Electrolyte Solutions
- Electrolytes
- Gastric Acid Lowering Agents
- Hemodialysis Solution
- I.V. Solution Additives
- Ions
- Irrigating Solutions
- Radiographic Contrast Agent
- Salt Solutions
- Sodium Compounds
- Urinary Alkalinisers
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as organic carbonic acids. These are compounds comprising the carbonic acid functional group.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Organic carbonic acids and derivatives
- Sub Class
- Organic carbonic acids
- Direct Parent
- Organic carbonic acids
- Alternative Parents
- Carbonate salts / Organic sodium salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Aliphatic acyclic compound / Carbonate salt / Carbonic acid / Carbonyl group / Hydrocarbon derivative / Organic alkali metal salt / Organic oxide / Organic oxygen compound / Organic salt / Organic sodium salt
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- one-carbon compound, organic sodium salt (CHEBI:32139)
Chemical Identifiers
- UNII
- 8MDF5V39QO
- CAS number
- 144-55-8
- InChI Key
- UIIMBOGNXHQVGW-UHFFFAOYSA-M
- InChI
- InChI=1S/CH2O3.Na/c2-1(3)4;/h(H2,2,3,4);/q;+1/p-1
- IUPAC Name
- sodium hydrogen carbonate
- SMILES
- [Na+].OC([O-])=O
References
- Synthesis Reference
Alan B. Gancy, Rustom P. Poncha, "Production of low bulk density product from sodium bicarbonate by the use of an inert gas stream." U.S. Patent US3984527, issued August, 1922.
US3984527- General References
- External Links
- KEGG Drug
- D01203
- KEGG Compound
- C12603
- PubChem Compound
- 516892
- PubChem Substance
- 46507049
- ChemSpider
- 8609
- 36676
- ChEBI
- 32139
- ChEMBL
- CHEMBL1353
- Therapeutic Targets Database
- DAP000128
- PharmGKB
- PA451375
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Sodium_bicarbonate
- AHFS Codes
- 40:08.00 — Alkalinizing Agents
- 56:04.00 — Antacids and Adsorbents
- 40:34.00* — Hemodialysis Solution
- MSDS
- Download (74 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Active Not Recruiting Prevention Catheter Complications / End Stage Renal Disease (ESRD) / Hemodialysis Access Failure / Hemodialysis Catheter Infection / Vascular Access Complications 1 4 Active Not Recruiting Treatment Varicosities of the great saphenous vein 1 4 Completed Not Available Colonoscopy 1 4 Completed Not Available Normal Healthy Subject Population 1 4 Completed Not Available Pain of Anesthesia at Breast Biopsy 1 4 Completed Diagnostic Anatomic renal artery stenosis / Chronic Kidney Disease (CKD) / Pulmonary Cancer / Pulmonary Embolism 1 4 Completed Prevention Acute Kidney Injury (AKI) 1 4 Completed Prevention Acute Renal Failure (ARF) / End Stage Renal Disease (ESRD) / Hemodialysis Access Failure / Hemodialysis Catheter Infection / Hemodialysis Catheter-Associated Bacteremia / Hemodialysis Complication 1 4 Completed Prevention Contrast Induced Acute Kidney Injury 1 4 Completed Prevention Contrast Induced Nephropathy (CIN) / Prophylaxis of Contrast-induced nephropathy 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Alaven Pharmaceutical
- Alcon Laboratories
- American Regent
- Amphastar Pharmaceuticals
- APP Pharmaceuticals
- A-S Medication Solutions LLC
- Atlantic Biologicals Corporation
- B. Braun Melsungen AG
- C.O. Truxton Inc.
- Cardinal Health
- Claris Lifesciences Inc.
- Concord Labs
- Consolidated Medical Imaging
- Cura Pharmaceutical Co. Inc.
- Dispensing Solutions
- Fresenius Kabi AB
- General Injectables and Vaccines Inc.
- Hospira Inc.
- Humco
- Luitpold Pharmaceuticals Inc.
- Mckesson Corp.
- Mylan
- Norwich Pharmaceuticals Inc.
- Physicians Total Care Inc.
- Prasco Labs
- QOL Medical
- Sandhills Packaging Inc.
- Santarus Inc.
- Dosage Forms
Form Route Strength Injection, solution 257 mg/1L Solution Hemodialysis 6.12 g/L Solution Hemodialysis 0.257 g/1000ml Solution Hemodialysis 2.94 g/1000ml Solution Hemodialysis 7.52 g/L Solution Extracorporeal 7.52 g/L Liquid Topical 50 mg/1mL Liquid Topical 5 g/100g Swab Topical 50 mg/1mL Suspension Oral 2.5 mg Suspension Oral 2.5 g Tablet, effervescent Oral 500 mg Tablet, effervescent Oral 324 mg Tablet, effervescent Oral Tablet Oral 324 mg Tablet, effervescent Oral 1.223 g Powder Oral 500 mg Injection, powder, for suspension Hemodialysis 750 mg Powder, for solution Intraocular Capsule Oral 500 mg Liquid Topical Powder, for solution Oral 227 g Tablet, chewable Oral 250 mg Liquid Topical 5 g/100mL Solution Intravenous 8.4 % Injection Intravenous 5 % Solution Hemodialysis; Topical 8.4 g Powder Oral Powder, for solution Oral 100 g Powder, for solution Hemodialysis Syrup 50 mg/5mL Kit; powder, for solution; tablet, delayed release Oral Powder, for solution Hemodialysis 100 g Injection, powder, for solution Hemodialysis 100 g Liquid Hemodialysis Solution Hemodialysis Liquid Hemodialysis Solution Intravenous 0.8401 g Solution Intravenous 840 mg Solution Intravenous 0.84 g Solution Parenteral 840 mg Injection, powder, lyophilized, for solution Hemodialysis 8.125 g Solution Intravenous 840.1 mg Kit; powder, for solution Hemodialysis Solution Intraperitoneal 16.5 g/L Injection, solution Intraperitoneal 30 g Solution Intraperitoneal 5.786 g/L Injection, solution Intraperitoneal 50 g Solution Intraperitoneal 0.1838 g/L Injection, solution Intraperitoneal 85 g Solution Hemodialysis; Intravenous 3.05 g/L Solution Intravenous 3.05 g/L Granule, effervescent Oral 0.65 g Granule, effervescent Oral 0.5 g Granule, effervescent Oral Granule, effervescent Oral 1.02 g/5g Granule, effervescent Oral Kit; solution Intraocular Solution Irrigation 0.433 mg/1mL Liquid Intravenous Tablet 65 mg Suppository Rectal Kit Intravenous Solution 970 mg/100mL Powder, for solution Nasogastric Powder, for solution Oral 45 g/750mL Solution Hemodialysis; Topical 6.5527 g Solution, concentrate Hemodialysis 99 g Injection, powder, lyophilized, for solution Hemodialysis 264.6 g Powder Nasal Powder 715.2 mg Solution Topical 1.25 g/100mL Liquid Oral 525 mg/15mL Solution Parenteral 8.4 g Tablet, chewable Oral 500 mg Injection Intravenous 84 mg/ml Solution Intravenous 4.21 g/1000ml Solution Hemodialysis 1.98 g/1000ml Solution Hemodialysis 0.91 g/1000ml Solution Intravenous 1.098 g/L Solution Hemodialysis 10.39 g/L Injection, solution Intravenous 10.39 g/L Liquid Oral 25 mg/1mL Injection, solution Intravenous 4.96 g/L Injection Intrathecal Powder, for solution Oral 52500 g Powder Oral 52.5 g Powder Oral 2.5 g Powder 1.85 g Powder 43.16 g Powder 1.85 g/4.3g Powder 43.16 g/100g Powder 43.26 g/100g Powder 43.11 g Powder 43.11 g/100g Powder, for solution Oral 45.49 % Powder, for solution Oral 46.4 % Powder, for solution Oral 1.85 g Powder, for solution Oral 45.32 % Powder, for solution Oral 45.55 % Powder, for solution Oral 43.35 % Injection, solution Intraperitoneal 0.1838 g/l Powder Oral 20 mg Suspension Oral 1.75 g Powder, for solution Oral 0.75 g/73.69g Granule Hemodialysis 100 g Tablet Oral 500 mg Liquid Oral 500 mg Tablet 650 mg Suspension Oral 5 g Suspension Oral 5 mg Suspension Oral 500 mg Suspension Oral 500 mg/10mL Suspension Oral 80 mg/5mL Tablet, chewable Oral 170 mg Tablet, chewable Oral 80 mg Suspension Oral 5 % w/v Tablet Oral 80 mg Suspension Oral 213 mg/10ml Tablet, chewable Oral 160 mg Suspension Oral 325 mg/10mL Tablet, chewable Oral 187.5 mg Liquid Oral 250 mg Suspension Oral 160 mg Tablet Oral 250 mg Tablet, chewable Buccal 250 mg Granule, effervescent Oral 5 mg Powder, for solution Oral 1 g/1g Powder, for solution Nasogastric; Oral Powder Topical 165 g/300g Solution Hemodialysis 2.4 g/1000ml Solution Intravenous 2.57 g/L Kit Oral Solution, concentrate 84 g/1L Powder, for solution Hemodialysis Solution Hemodialysis; Intravenous 2.033 g/L Solution Hemodialysis 8.4 g Suspension Oral 213 mg Injection, solution Intravenous 12.18 g/1000ml Injection, solution Intravenous 12.18 g/L Injection, solution Intravenous 14 g/1000ml Injection, solution Intravenous 14 g/L Solution Oral 3.3 % w/v Powder Oral 1000 mg/1g Granule Oral Powder, for solution Oral 14.75 G Powder, for solution Oral 29.5 G Powder, for solution Oral 7.375 G Powder, for solution Oral 1.685 g Powder, for solution Oral 0.05 g Powder, for solution Oral 0.3507 g Suppository Rectal 0.54 g Tablet Topical 60 g/100g Powder Oral 5 g/100mL Powder Oral 71 mg Tablet Oral 71 mg Tablet Transmucosal 71 mg Injection 8.4 % Tablet, chewable Oral 200 mg Suspension Oral 0.5 g Suspension Oral 250 mg Solution Oral 3.33 %w/w Solution Intravenous 0.84 g/10ml Powder, for solution Oral 13.125 g Solution Oral 13.125 g Powder, for solution Oral 350.7 mg Tablet Oral 200 mg Powder, for solution Oral 6.563 G Powder, for solution Oral 0.1785 g Powder, for solution Oral 0.0251 g Solution, concentrate Oral 0.3507 g Solution Hemodialysis 0.2205 g/1000ml Injection, solution Hemodialysis; Intravenous 6.136 g/1000ml Solution Hemodialysis; Intravenous 0.1017 g/L Solution Hemodialysis 0.2205 g/L Solution / drops Auricular (otic) 17.84 g/100mL Injection, solution 250 mg/5mL Solution Intravenous 1.68 g Injection, solution, concentrate Parenteral 8.4 % Capsule, delayed release Oral 500 mg Kit; solution Intraocular; Irrigation Capsule, delayed release Oral 840 mg Injection, solution Intravenous 0.2 g/5mL Powder, for solution Oral 118 g Liquid Oral 160 mg/10ml Tablet, delayed release Oral 1000 mg Solution Oral Tablet Oral For suspension Oral Powder, for suspension Oral Liquid; mouthwash Oral Powder, for solution Oral 59 g Paste Dental 0.204 % Injection, solution Intramuscular 84 mg/1mL Powder, for solution Oral 568 mg Powder, for solution Oral 120 g/129.2g Powder, for solution Oral 46.6 mg Injection Intravenous 8.4 % w/v Injection, solution Intravenous 3.68 g/1L Solution Hemodialysis 0.225 g/1000ml Solution Hemodialysis 3.68 g/L Solution Intraperitoneal 13.6 g/1000ml Solution Intraperitoneal 22.7 g/1000ml Solution Intraperitoneal 38.6 g/1000ml Solution Intraperitoneal 15 g/L Solution Intraperitoneal 25 g/L Solution Intravenous 25 g/L Solution Intraperitoneal 42.5 g/L Solution Intraperitoneal 2.1 g/1000ml Solution Hemodialysis Powder Oral Powder, for solution Oral Kit Hemodialysis Solution Intravenous Solution Hemodialysis; Intravenous Solution Intravenous 2.033 g/L Solution Hemodialysis 0.257 g/L Injection, solution 514.5 mg/100mL Injection Intravenous Solution Hemodialysis 0.258 g/L Lotion Topical Suspension Oral 250 mg/5ml Kit Dental Solution Oral 11 % Powder, for suspension Oral 20 mg Suspension Oral 21.3 mg/ml Suspension Oral 267 mg/ml Suspension Oral 50 mg/ml Liquid Oral Solution Oral 1 g/5ml Solution Oral 250 mg Powder, for solution Oral 56.6 g Granule, effervescent Oral 2.83 g Granule, effervescent Oral 1.415 g Granule, effervescent Oral 2830 mg Powder, for solution Oral 0.5 g Granule, effervescent Oral 56.6 g Solution Oral 1 g/100mL Powder, for solution Oral 14.58 G Powder, for solution Oral 58.32 G Powder, for solution Oral 14.57 g Powder, for solution Oral 58.3 g Powder, for solution Nasal Solution / drops Auricular (otic) 3 g/100mL Solution / drops Auricular (otic) 5 g/100mL Tablet 300 mg Injection, solution Intravenous 1.4 % Tablet Parenteral 500 MG Injection, solution Parenteral 1 MEQ/1ML Injection, solution Parenteral 8.4 G/100MG Injection, solution Parenteral 1 MEQ/ML Injection, solution Parenteral 1 MEQ/10ML Injection, solution Parenteral 1.4 % Injection, solution Parenteral 5 % Injection, solution Parenteral 7.5 % Injection, solution Parenteral 8.4 % Injection, solution, concentrate Intravenous 1 MEQ/ML Injection, solution Parenteral 10 MEQ/10ML Injection, solution, concentrate Intravenous 10 MEQ/10ML Solution / drops Auricular (otic) 1 g/100mL Injection, solution 7.5 g/100mL Solution / drops Auricular (otic) 7.5 g/100mL Injection Intravenous 84 mg/1mL Injection Parenteral 42 mg/1mL Injection Parenteral 84 mg/1mL Injection, solution 8.4 g/100mL Injection, solution Intravenous 1 meq/1mL Injection, solution Intravenous 42 mg/1mL Injection, solution Intravenous 44.6 meq/50mL Injection, solution Intravenous 7.5 g/100mL Injection, solution Intravenous 75 mg/1mL Injection, solution Intravenous 84 mg/1mL Powder Oral; Topical 100 % Solution Intravenous 42 mg/1mL Solution Intravenous 84 mg/1mL Solution Parenteral 84 mg/1mL Syrup 50 g/5mL Tablet 500 MG Tablet Oral 650 mg/1 Tablet, orally disintegrating Oral 650 mg/1 Tablet Oral 648 mg/1 Solution / drops Auricular (otic); Ophthalmic 2.5 g/100mL Tablet Oral 324 mg/1 Tablet Oral 325 mg/1 Solution Intravenous Powder Oral 2.52 g/2.52g Powder Oral 2.6 g/2.6g Powder Oral 2.616 g/2.616g Solution / drops Auricular (otic) 2.5 g/100mL Liquid Intravenous Powder, for solution Oral 50 g Tablet Oral Powder Hemodialysis Powder Hemodialysis Injection, solution Intravenous 8.4 % Solution Extracorporeal 0.42 g/L Solution Extracorporeal 6.43 g/L Solution Extracorporeal 0.42 g/20ml Solution Extracorporeal 3.22 g/480ml Solution 1.05 g/L Capsule Oral Powder, for solution Oral 9.09 g Powder, for solution Hemodialysis 6.6 g Solution Hemodialysis 6.6 g Injection, powder, for solution Intravenous 0.23 mg Kit; powder, for solution Intravenous 0.23 MG Cream Topical 50 mg/1g Capsule, gelatin coated Oral Powder, for solution Oral 1.43 g Injection, solution Intravenous 840 mg/10ml Granule, for solution Oral 6.25 mg Powder, for solution Oral 375 mg Granule, for solution Oral 0.63 g Granule, effervescent Oral 720 mg Granule, effervescent Oral 720 mg/4g Solution Oral 8.4 g/100mL Solution / drops Auricular (otic) 2.6 g/100mL Kit Nasal Granule, for solution Nasal Tablet, chewable Oral Solution Oral 13.5 mg/15mL - Prices
Unit description Cost Unit Golytely 236 gm Solution 28.0USD bottle Colyte 240 gm Solution 26.0USD bottle Golytely 227.1 gm Solution Packet 21.85USD packet Colyte-Flavored 240 gm Solution 18.17USD bottle Elliotts b solution ampule 4.71USD ml Sodium bicarb 4.2% vial 1.45USD ml Neut 4% vial 0.92USD ml Bss plus eye solution 0.2USD ml Sodium bicarb 650 mg tablet 0.07USD tablet Antacid 650 mg tablet 0.05USD tablet Antacid 325 mg tablet 0.04USD tablet Sodium bicarb 325 mg tablet 0.04USD tablet Sodium bicarb 7.5% vial 0.04USD ml Sodium bicarbonate powder 0.03USD g Sodium bicarb 8.4% vial 0.02USD ml Sodium bicarbonate 5% inj 0.02USD ml Colyte with flavor packets 0.01USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region Unlock Additional DataUS6489346 No 2002-12-03 2016-07-16 US US6699885 No 2004-03-02 2016-07-16 US USRE45198 No 2014-10-14 2016-07-16 US US6645988 No 2003-11-11 2016-07-16 US US7399772 No 2008-07-15 2016-07-16 US US5945449 No 1999-08-31 2017-10-31 US US7300674 No 2007-11-27 2023-03-04 US US7291324 No 2007-11-06 2022-10-22 US US5840737 No 1998-11-24 2016-07-15 US US6780882 No 2004-08-24 2016-07-15 US US7084130 No 2006-08-01 2021-11-29 US Additional Data Available- Filed OnFiled OnAvailable for Purchase
The date on which a patent was filed with the relevant government.
Learn more
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) Decomposes around 50 °C Not Available water solubility 1E+005 mg/L (at 25 °C) MERCK INDEX (1996) pKa 6.3 Not Available - Predicted Properties
Property Value Source Water Solubility 764.0 mg/mL ALOGPS logP -0.06 ALOGPS logP 0.25 ChemAxon logS 0.96 ALOGPS pKa (Strongest Acidic) 6.05 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 60.36 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 20.34 m3·mol-1 ChemAxon Polarizability 3.86 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9292 Blood Brain Barrier + 0.936 Caco-2 permeable - 0.5321 P-glycoprotein substrate Non-substrate 0.8785 P-glycoprotein inhibitor I Non-inhibitor 0.9903 P-glycoprotein inhibitor II Non-inhibitor 0.9931 Renal organic cation transporter Non-inhibitor 0.9563 CYP450 2C9 substrate Non-substrate 0.8326 CYP450 2D6 substrate Non-substrate 0.9017 CYP450 3A4 substrate Non-substrate 0.8144 CYP450 1A2 substrate Non-inhibitor 0.9053 CYP450 2C9 inhibitor Non-inhibitor 0.9337 CYP450 2D6 inhibitor Non-inhibitor 0.9401 CYP450 2C19 inhibitor Non-inhibitor 0.9461 CYP450 3A4 inhibitor Non-inhibitor 0.9774 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9911 Ames test Non AMES toxic 0.9285 Carcinogenicity Non-carcinogens 0.5181 Biodegradation Ready biodegradable 0.9636 Rat acute toxicity 1.9204 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9596 hERG inhibition (predictor II) Non-inhibitor 0.9866
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available
Targets
Yes
Neutralizer
References
- Nudel DB, Peterson BJ, Buckley BJ, Kaplan NA, Weinhaouse E, Gootman N: Comparative effects of bicarbonate and dichloroacetate in newborn swine with hypoxic lactic acidosis. Dev Pharmacol Ther. 1990;15(2):86-93. [PubMed:1964114]
- Roderick P, Willis NS, Blakeley S, Jones C, Tomson C: Correction of chronic metabolic acidosis for chronic kidney disease patients. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001890. [PubMed:17253467]
- Balali-Mood M, Balali-Mood K: Neurotoxic disorders of organophosphorus compounds and their managements. Arch Iran Med. 2008 Jan;11(1):65-89. [PubMed:18154426]
- Vaughan-Jones RD, Spitzer KW: Role of bicarbonate in the regulation of intracellular pH in the mammalian ventricular myocyte. Biochem Cell Biol. 2002;80(5):579-96. [PubMed:12440699]
- Levraut J, Giunti C, Ciebiera JP, de Sousa G, Ramhani R, Payan P, Grimaud D: Initial effect of sodium bicarbonate on intracellular pH depends on the extracellular nonbicarbonate buffering capacity. Crit Care Med. 2001 May;29(5):1033-9. [PubMed:11378618]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Sodium:bicarbonate symporter activity
- Specific Function
- Electrogenic sodium/bicarbonate cotransporter with a Na(+):HCO3(-) stoichiometry varying from 1:2 to 1:3. May regulate bicarbonate influx/efflux at the basolateral membrane of cells and regulate in...
- Gene Name
- SLC4A4
- Uniprot ID
- Q9Y6R1
- Uniprot Name
- Electrogenic sodium bicarbonate cotransporter 1
- Molecular Weight
- 121459.38 Da
References
- Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. [PubMed:17071329]
- Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. [PubMed:15014910]
- Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. [PubMed:12847417]
- Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. [PubMed:12027220]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Sodium:bicarbonate symporter activity
- Specific Function
- Electroneutral sodium- and bicarbonate-dependent cotransporter with a Na(+):HCO3(-) 1:1 stoichiometry. Regulates intracellular pH and may play a role in bicarbonate salvage in secretory epithelia. ...
- Gene Name
- SLC4A7
- Uniprot ID
- Q9Y6M7
- Uniprot Name
- Sodium bicarbonate cotransporter 3
- Molecular Weight
- 136042.595 Da
References
- Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. [PubMed:17071329]
- Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. [PubMed:15014910]
- Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. [PubMed:12847417]
- Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. [PubMed:12027220]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Sodium:bicarbonate symporter activity
- Specific Function
- Mediates electroneutral sodium- and carbonate-dependent chloride-HCO3(-) exchange with a Na(+):HCO3(-) stoichiometry of 2:1. Plays a major role in pH regulation in neurons. May be involved in cell ...
- Gene Name
- SLC4A8
- Uniprot ID
- Q2Y0W8
- Uniprot Name
- Electroneutral sodium bicarbonate exchanger 1
- Molecular Weight
- 122936.66 Da
References
- Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. [PubMed:17071329]
- Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. [PubMed:15014910]
- Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. [PubMed:12847417]
- Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. [PubMed:12027220]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Sodium:bicarbonate symporter activity
- Specific Function
- Mediates sodium- and bicarbonate-dependent electrogenic sodium bicarbonate cotransport, with a Na(+):HCO3(-) stoichiometry of 2:1. May have a housekeeping function in regulating the pH of tissues i...
- Gene Name
- SLC4A5
- Uniprot ID
- Q9BY07
- Uniprot Name
- Electrogenic sodium bicarbonate cotransporter 4
- Molecular Weight
- 126254.04 Da
References
- Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. [PubMed:17071329]
- Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. [PubMed:15014910]
- Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. [PubMed:12847417]
- Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. [PubMed:12027220]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Sodium:bicarbonate symporter activity
- Specific Function
- Electrogenic sodium/bicarbonate cotransporter in exchange for intracellular chloride. Plays an important role in regulating intracellular pH (By similarity).
- Gene Name
- SLC4A10
- Uniprot ID
- Q6U841
- Uniprot Name
- Sodium-driven chloride bicarbonate exchanger
- Molecular Weight
- 125945.115 Da
References
- Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. [PubMed:17071329]
- Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. [PubMed:15014910]
- Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. [PubMed:12847417]
- Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. [PubMed:12027220]
Drug created on July 08, 2007 10:59 / Updated on January 23, 2021 21:03